With a growing number of complex cell and gene therapies approved globally, mostly for rare disease populations, manufacturers are looking at how to make these products more accessible by delivering available treatments through a greater number of health care centers and by developing new treatments for larger patient populations.
Key Takeaways
-
Cell and gene therapy developers want to bring their products to more patients via health care providers closer to home and larger indications.
-
However, community health care providers have limited resources to provide the specialized treatment administration and safety monitoring that cell and gene therapies provide
Launches for approved cell and gene therapies to treat rare diseases and small oncology indications at a limited number of authorized or qualified treatment centers (ATCs or QTCs) – usually academic institutions, transplant centers or regional facilities that have clinical trial experience with these products – have been difficult, to say the least
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?